UK markets close in 6 hours
  • FTSE 100

    7,096.96
    +22.90 (+0.32%)
     
  • FTSE 250

    22,628.91
    -30.51 (-0.13%)
     
  • AIM

    1,232.17
    +1.08 (+0.09%)
     
  • GBP/EUR

    1.1702
    +0.0001 (+0.01%)
     
  • GBP/USD

    1.3961
    -0.0003 (-0.02%)
     
  • BTC-GBP

    23,829.11
    -674.46 (-2.75%)
     
  • CMC Crypto 200

    804.22
    -5.97 (-0.74%)
     
  • S&P 500

    4,241.84
    -4.60 (-0.11%)
     
  • DOW

    33,874.24
    -71.34 (-0.21%)
     
  • CRUDE OIL

    73.31
    +0.23 (+0.31%)
     
  • GOLD FUTURES

    1,781.10
    -2.30 (-0.13%)
     
  • NIKKEI 225

    28,875.23
    +0.34 (+0.00%)
     
  • HANG SENG

    28,882.46
    +65.39 (+0.23%)
     
  • DAX

    15,587.87
    +131.48 (+0.85%)
     
  • CAC 40

    6,617.89
    +66.82 (+1.02%)
     

Transaction in own shares

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
  • Oops!
    Something went wrong.
    Please try again later.

Arix Bioscience PLC (ARIX)
03-Jun-2021 / 17:33 GMT/BST
Dissemination of a Regulatory Announcement, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Arix Bioscience plc

 

Transaction in own shares

 

LONDON, 03 June 2021: Arix Bioscience plc ("Arix" or "the Company") (LSE:ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today announces that it purchased the following number of its ordinary shares of 0.001 pence each on the London Stock Exchange from Jefferies International Limited as part of a buyback programme announced on 22 March 2021.

 

Date of purchase

03 June 2021

Aggregate number of shares purchased

40,000

Highest price paid per share

179.00p

Lowest price paid per share

178.70p

Average price paid per share

178.96p

 

Arix intends to retain the purchased shares in treasury.

Following settlement of the above purchase, Arix will have 131,885,800 ordinary shares of 0.001 pence each in issue (excluding 3,723,853 ordinary shares of 0.001 pence each held in treasury). This number represents the total voting rights in Arix and may be used by shareholders as the denominator for the calculations by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.             

In accordance with Article 5(1)(b) of Regulation (EU) No. 596/2014 (as incorporated into UK domestic law by the European Union (Withdrawal) Act 2018), the schedule below contains detailed information of the individual trades made by Jefferies International Limited as part of the buyback programme.

[ENDS]

 

For more information on Arix, please contact:

 

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

+44 (0)20 7290 1072

charlotte@arixbioscience.com

 

 

Optimum Strategic Communications

Mary Clark, Supriya Mathur, Shabnam Bashir

+44 (0)20 3922 1906

optimum.arix@optimumcomms.com

 

 

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 

 

Transaction Date

Transaction Time

Volume

Price (GBp)

Platform

Transaction Reference Number

03/06/2021

14:02:01

10,000

179.00

London Stock Exchange

00244402467TRLO1

03/06/2021

16:24:40

5,000

178.70

London Stock Exchange

00244563161TRLO1

03/06/2021

16:35:58

25,000

179.00

London Stock Exchange

00244572678TRLO1

 

  


ISIN:

GB00BD045071

Category Code:

POS

TIDM:

ARIX

LEI Code:

213800OVT3AHQCXNIX43

OAM Categories:

2.4. Acquisition or disposal of the issuer's own shares

Sequence No.:

109203

EQS News ID:

1204177


 

End of Announcement

EQS News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting